paricalcitol
Also known as Zemplar®, 19-Nor-1alpha,25-dihydroxyvitamin D2
Paricalcitol (chemically it is 19-nor-1,25-(OH)2-vitamin D2. Marketed by Abbott Laboratories under the trade name Zemplar) is a drug used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic kidney failure. It is an analog of 1,25-dihydroxyergocalciferol, the active form of vitamin D2 (ergocalciferol).
Research
852 papers- Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis.The Journal of clinical endocrinology and metabolism · 2023
- Paricalcitol plus hydroxychloroquine enhances gemcitabine activity and induces mesenchymal to epithelial transition in pancreatic ductal adenocarcinoma: A single cell RNA-seq analysis.Cancer letters · 2025
- Paricalcitol ameliorates diabetic nephropathy by promoting EETs and M2 macrophage polarization and inhibiting inflammation by regulating VDR/CYP2J2 axis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
- Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction.The oncologist · 2025
- Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis.Drug design, development and therapy · 2019
via PubMed
~5 min read
Article
8 sectionsContents
- Medical uses
- Adverse effects
- Contraindications
- Interactions
- Overdose
- Mechanism of action
- Pharmacokinetics
- References
Paricalcitol (chemically it is 19-nor-1,25-(OH)2-vitamin D2. Marketed by Abbott Laboratories under the trade name Zemplar) is a drug used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic kidney failure. It is an analog of 1,25-dihydroxyergocalciferol, the active form of vitamin D2 (ergocalciferol).
It was patented in 1989 and approved for medical use in 1998.